稳定过表达XAF1基因对A2780卵巢癌细胞生物学功能的影响

目的 构建稳定过表达XAF1基因A2780卵巢癌细胞株,并观察XAF1基因对卵巢癌细胞增殖、凋亡、细胞周期及对紫杉醇敏感性的影响。方法 分别将质粒pcDNA3.1（+）和pcDNA3.1（+）-XAF1转染至卵巢癌细胞A2780,通过质粒抗性标记（遗传霉素G418）筛选得到阴性对照细胞株（A2780/Negative control, A2780/NC）和稳定表达XAF1的细胞株（A2780/XAF1）;通过行细胞克隆形成实验和CCK8实验检测细胞增殖及对紫杉醇的敏感性,流式细胞仪检测细胞周期及细胞凋亡。结果 成功构建了稳定表达XAF1的卵巢癌细胞A2780/XAF1,细胞形态无明显变化;与A2780/NC相比,A2780/XAF1克隆形成能力能力更低（P= 0.0016）,细胞贴壁后第1天和第3天增殖活性更低（P=0.009,0.0035）,两组细胞的细胞周期分布差异存在统计学意义（P< 0.0001）,两两比较结果显示A2780/XAF1组G2-M期细胞百分比显著增加（P<0.001）。在无凋亡刺激、无血清培养及紫杉醇诱导下,A2780/XAF1的凋亡率均比A2780/NC更高（P<0.001）;在不同紫杉醇浓度作用下,A2780/XAF1的增殖活性均显著低于A2780/NC（P<0.001）,且A2780/XAF1的紫杉醇半数抑制浓度显著低于A2780/NC。结论 成功构建稳定表达XAF1的卵巢癌细胞A2780/XAF1;XAF1调控卵巢癌细胞A2780的增殖、凋亡及细胞周期,并增加了卵巢癌对紫杉醇的敏感性。     

OSTP增强紫杉醇诱导卵巢癌A2780细胞凋亡的作用

目的 研究卵巢癌特异性结合肽（OSTP）及联合紫杉醇对卵巢癌A2780细胞生长及凋亡的影响.方法 体外培养卵巢癌A2780细胞,随机分为4组：溶剂对照组（1640和0.1％ DMSO组）、OSTP组、紫杉醇组、OSTP联合紫杉醇组.采用四甲基偶氮唑盐（MTT法）检测OSTP对A2780细胞生长的影响;用Annexin-V-FITC和PI双染法标记A2780细胞,通过流式细胞仪检测细胞凋亡情况.结果 MTT法检测OSTP以不同浓度作用于卵巢癌A2780细胞时,可对该细胞的生长起到抑制作用,与对照组相比差异有统计学意义（P＜0.01）.应用流式细胞技术检测细胞凋亡发现：不同浓度的OSTP（20、40、80、160、320μmol/L）对A2780细胞的凋亡率分别7.88％、8.348％、8.727％、9.393％和10.68％,与对照组相比差异有统计学意义（P＜0.01）,提示OSTP可诱导细胞凋亡.OSTP和紫杉醇联合应用,在不同的预处理组（加OSTP80μ mol/L 0、3、6、12h）后再加紫杉醇10μmol/L作用48h,结果发现细胞凋亡率分别是39.40％、53.09％、48.18％和45.62％,均高于OSTP和紫杉醇单独用药及两者的凋亡率相加值,且差异有统计学意义（P ＜0.001）.提示OSTP能增强紫杉醇诱导的卵巢癌A2780细胞凋亡作用.结论 OSTP对卵巢癌A2780细胞有生长抑制及凋亡作用,尤其是OSTP能增强紫杉醇诱导卵巢癌A2780细胞凋亡的作用,对于探讨和开发OSTP作为靶向化疗增敏剂治疗卵巢癌有良好的应用前景.     

紫杉醇对人卵巢癌细胞凋亡的影响

目的 :探讨紫杉醇 (PTX)对人卵巢细胞凋亡的影响。方法 :应用细胞形态观察、琼脂糖凝胶电泳、流式细胞仪、活细胞视频观察和蛋白印迹免疫法进行检测和观察。结果 :癌细胞在PTX作用下 ,首先表现为G2 /M期阻滞 ,一定时间后出现细胞凋亡。凋亡细胞表现为细胞固缩 ,核染色质凝聚或断裂。细胞DNA裂解片段呈现典型的“阶梯状”排列的条带。凋亡抑制基因Bcl- 2在细胞凋亡过程中呈低表达并发生修饰反应 ,而调亡诱发基因Bax先呈高表达后表达降低。结论 :PTX诱发人卵巢癌细胞的凋亡与细胞分裂阻滞密切相关 ,Bcl- 2和Bax在PTX引起人卵巢癌细胞凋亡中可能起着重要的调控作用。     

17-AAG联合紫杉醇对Eca-109食管癌细胞增殖的抑制作用

目的研究17-AAG联合紫杉醇（PTX）对食管癌细胞Eca-109增殖和凋亡的影响。方法予以PTX和17-AAG单独或联合
使用作用于Eca-109细胞株,采用MTT法检测其细胞增殖的变化,应用流式细胞仪检测细胞周期、凋亡的变化。结果与对照组
相比,单独使用17-AAG、PTX均能够抑制Eca-109细胞的增殖;0.5 μmol/L PTX联合0.625 μmol/L 17-AAG可抑制Eca-109的生
长,且联合效应明显强于各自单药组（P<0.01）;流式细胞仪检测结果显示：17-AAG将Eca-109 细胞阻滞于G2/M 期,PTX将
Eca-109 细胞阻滞于S 期。17-AAG与PTX 联合用药使Eca-109 细胞阻滞于G2/M 期和S。17-AAG组、PTX组及联合组作用
Eca-109细胞株24 h后其凋亡率分别为4.52%、10.91%、29.88%,显著高于对照组（1.32%）;联合用药后,可形成明显凋亡峰,明显高
于单药组。结论PTX和17-AAG均可抑制食管癌细胞增殖,诱导癌细胞凋亡,两者联合可增强上述作用。
     

Targeting of p38 Mitogen-activated Protein Kinases to Early Growth Response gene 1 （EGR-1） in the Human Paclitaxel-resistance Ovarian Carcinoma Cells

To investigate the relationship between the expression of early growth response gene 1 (EGR-1) and p38MAPK pathway in the paclitaxel resistance of ovarian carcinoma cells, the effect of p38MAPK inhibitor SB203580 on cell apoptosis was examined by using Hoechst 33258 staining. The intracellular Rh123 (Rhodamine 123) accumulation was detected by the flow cytometry (FCM). The 50% inhibition concentration (IC50) of paclitaxel for A2780/Taxol cells was determined by MTT method. Electrophoretic motility shift assay (EMSA) was employed to examine the EGR-1DNA binding activity. MDR1 and EGR-1 mRNA were assessed by RT-PCR. The expressed of p-gp, phos- phorylated p53 and p38 were detected by Western blotting. SB203580 could remarkably promote the apoptosis of A2780/Taxol cells, and the cell apoptosis was in a time-dependent manner. Cellular Rh123 accumulation was increased, and the IC50 of paclitaxel for A2780/Taxol cells was decreased significantly. A2780/Taxol cell line after SB203580 treatment was shown to have a significantly higher level of EGR-1 DNA binding activity. SB203580 down-regulated the activity of p38MAPK pathway, but up-regulated EGR-1 expression. SB203580 significantly increased the level of cellular phosphorylated p53 protein, but decreased the p-gp protein level and MDR1 mRNA level in A2780/Taxol cells. There existed a close relationship between p38MAPK pathway and the paclitaxel resistance of ovarian carcinoma cells. The expression of EGR-1 mediated by p38MAPK pathway plays a critical role in paclitaxel resistance of ovarian carcinoma cells.     

XIAP基因与耐紫杉醇卵巢癌细胞A2780/Taxol耐药关系的研究

目的 探讨X连锁凋亡抑制蛋白（XIAP）基因与卵巢癌对紫杉醇耐药的相关性。方法 以5、10、20、40、80、160、320 ng/mL的紫杉醇处理卵巢癌紫杉醇敏感细胞A2780和耐药细胞A2780/T,噻唑蓝（MTT）比色法检测各组细胞的抑制率（IR）, 逆转录实时荧光定量PCR（RT-qPCR）、蛋白质印记（Western blot）检测紫杉醇100 ng/mL处理A2780和A2780/T细胞后XIAP基因和蛋白的表达;将A2780/T细胞分为空转染组（转染空载体质粒）、小干扰RNA（siRNA）-XIAP（siRNA-XIAP）组（转染siRNA-XIAP质粒）、非特异性转染组（转染非特异性质粒）、空白对照组（不转染质粒）,RT-qPCR和Western blot检测各组细胞XIAP基因和蛋白的表达,并加入含不同质量浓度的紫杉醇（0、1 000、1 500、2 000、2 500 ng/mL）,流式细胞仪检测细胞凋亡率。结果 不同质量浓度紫杉醇处理后,A2780细胞IR随紫杉醇质量浓度的增加而增高（P<0.05）,A2780/T细胞IR无明显变化。紫杉醇100 ng/mL处理A2780和A2780/T细胞后,A2780细胞XIAP mRNA的表达低于紫杉醇未处理组（P<0.05）,A2780/T细胞中XIAP mRNA的表达与紫杉醇未处理组差异无统计学意义(P>0.05),但A2780/T细胞XIAP mRNA和蛋白表达均高于A2780紫杉醇处理组（P均<0.05）;siRNA-XIAP组XIAP mRNA和蛋白的表达均低于其他各组（P<0.05）,在紫杉醇2 000 ng/mL及2 500 ng/mL作用下,siRNA-XIAP组凋亡率高于其他各组（P<0.05）。结论 卵巢癌对紫杉醇耐药与XIAP基因的高表达有关,特异性的siRNA可通过降低XIAP的表达,促进细胞凋亡,增加耐药癌细胞对紫杉醇的敏感性。     

白藜芦醇与紫杉醇联合应用对肺癌细胞PC9的杀伤效应

目的:探讨白藜芦醇(RES)联合紫杉醇(PTX)对人肺癌细胞PC9的凋亡作用及其机制。方法:不同浓度的RES和PTX单用和联合作用于PC9细胞后,分别采用四甲基偶氮唑蓝法测定其对PC9的增殖抑制作用,流式细胞术检测其对细胞周期分布和凋亡的影响,Western blot法检测Caspase-3蛋白、抗凋亡蛋白Bcl-2、促凋亡Bax表达的变化。结果:10、20、30 μmol/L的RES和0.001、0.01、0.1 μmol/L的PTX均以时间和浓度依赖方式抑制PC9细胞的增殖,RES联合PTX的抑制率高于RES和PTX单用组(P<0.01)。单用RES和PTX均能诱导PC9细胞发生凋亡和G₀/G₁期阻滞,两者联合应用,诱导细胞凋亡和G₀/G₁期阻滞作用显著增强(P<0.01)。Western blot法检测显示在RES和PTX联用之后,Caspase-3蛋白、Bcl-2、Bax的改变显著大于单药作用。结论:RES、PTX均可抑制人肺癌PC9细胞增殖、诱导其凋亡、阻滞细胞G₀/G₁期、伴随Caspase-3活性上调,且两者联合应用具有协同作用,可显著促进细胞凋亡,其机制可能与上调凋亡蛋白Bcl-2、下调抗凋亡蛋白Bax有关。     

The Relationship between p38MAPK and Apoptosis during Paclitaxei Resistance of Ovarian Cancer Cells

To investigate the relationship between p38 mitogen-activated protein kinase (p38MAPK) and cell apoptosis during the paclitaxel resistance of ovarian carcinoma cell lines, flow cytometry (FCM) and PI staining were employed to determine the effect of p38MAPK inhibitor SB203580 on the apoptosis of A2780/Taxol cells, a drug-resistant human ovarian carcinoma cell line. p38MAPK protein expression in SB203580-treated cells was immunochemically measured. The 50% inhibition concentration (IC(50)) of paclitaxel on A2780/Taxol cells was determined by MTT assay. MDR-1 mRNA, and expression of p38MAPK and phospho-p53 protein were detected by RT-PCR and Western blotting, respectively. The apoptosis rate of A2780/Taxol cells was (19.7+/-1.04)% 24 h after SB203580 treatment. A significant difference in apoptosis rate was found among experiment group, control group and untreated group (P<0.05). The relative reversal rate of A2780/Taxol cells to paclitaxel was (57.18+/-2.01)%. As compared with the control group and the untreated group, p38MAPK protein and MDR-1 mRNA in SB203580-treated cells was substantially decreased. The expression of p53 protein was significantly increased. It is concluded that p38MAPK pathway is related to paclitaxel resistance of ovarian carcinoma, and blockade of this pathway can promote the apoptosis of the drug-resistant cells and reverse the drug-resistance. Moreover, p38MAPK-mediated apoptosis in paclitaxel-resistant ovarian carcinoma cells depends on the activation of p53.     

低频超声联合微泡造影剂通过激活内质网应激逆转前列腺癌紫杉醇耐药

目的 探讨低频超声联合微泡造影剂辅助紫杉醇逆转前列腺癌耐药的作用和机制.方法 筛选超声辐照紫杉醇耐药前列腺癌细胞株PC-3R的非毒性照射时间;将PC-3R细胞随机分为对照组、紫杉醇组(PTX组)、低频超声组(LFUS组)、紫杉醇和低频超声组(PTX+LFUS组),以及紫杉醇和低频超声联合微泡剂组(PTX+ LFUS+ UCA组),分别进行干预.AnnexinV-FITC/PI双染法检测各组细胞凋亡;q-PCR法检测各组细胞Bcl-2和多耐药基因表达变化;Western blot检测各组细胞GRP78和c-jun蛋白表达.GRP78 siRNA转染PC-3R细胞,微泡和低频超声联合处理后,Western blot检测GRP78蛋白表达,Annexin V-FITC/PI双染法检测凋亡情况.结果 低频超声照射频率1 MHz,强度1.2 W/cm2,非毒性照射时间为10 s.与单纯应用紫杉醇相比低频超声辅助紫杉醇处理前列腺耐药细胞可显著提高细胞凋亡率(P＜0.01),联合微泡剂照射后,凋亡率进一步提高(P＜0.01),并下调Bcl-2和多耐药基因的表达.PTX+ LFUS+UCA组内质网应激相关蛋白GRP78的表达较PTX组和PTX+LFUS组升高,c-jun的表达下降(P＜0.01).应用siRNA干扰GRP78基因表达后,细胞凋亡率下降(P＜0.01).结论 低频超声联合微泡造影剂通过激活内质网应激,抑制其下游JNK/c-jun通路下调多耐药基因及凋亡抑制基因的表达,提高化疗药物诱导细胞凋亡的作用,逆转肿瘤细胞的耐药性.     

8-溴-7-甲氧基白杨素对顺铂耐药卵巢癌A2780/DDP细胞凋亡的影响

目的:研究8-溴-7-甲氧基白杨素(8-bromo-7-methoxychrysin,BrMC)诱导人顺铂耐药卵巢癌A2780/DDP细胞凋亡作用及细胞凋亡过程中Akt蛋白磷酸化水平的变化。方法:用不同浓度的BrMC处理体外培养的A2780/DDP细胞,碘化丙啶(PI)染色流式细胞术(FCM)和细胞凋亡ELISA检测试剂盒检测凋亡性细胞死亡,Western Blot分析Akt蛋白磷酸化水平。结果:BrMC具有诱导A2780/DDP细胞凋亡作用,并且随药物浓度的增加而增强;同时BrMC以浓度依赖的方式下降Akt蛋白磷酸化水平。结论:BrMC诱导A2780/DDP细胞凋亡与其抑制Akt活化相关。     

The relationship between p38MAPK and apoptosis during paclitaxel resistance of ovarian cancer cells

Summary To investigate the relationship between p38 mitogen-activated protein kinase (p38MAPK) and cell apoptosis during the paclitaxel resistance of ovarian carcinoma cell lines, flow cytometry (FCM) and PI staining were employed to determine the effect of p38MAPK inhibitor SB203580 on the apoptosis of A2780/Taxol cells, a drug-resistant human ovarian carcinoma cell line. p38MAPK protein expression in SB203580-treated cells was immunochemically measured. The 50% inhibition concentration (IC₅₀) of paclitaxel on A2780/Taxol cells was determined by MTT assay. MDR-1 mRNA, and expression of p38MAPK and phospho-p53 protein were detected by RT-PCR and Western blotting, respectively. The apoptosis rate of A2780/Taxol cells was (19.7±1.04)% 24 h after SB203580 treatment. A significant difference in apoptosis rate was found among experiment group, control group and untreated group (P<0.05). The relative reversal rate of A2780/Taxol cells to paclitaxel was (57.18±2.01)%. As compared with the control group and the untreated group, p38MAPK protein and MDR-1 mRNA in SB203580-treated cells was substantially decreased. The expression of p53 protein was significantly increased. It is concluded that p38MAPK pathway is related to paclitaxel resistance of ovarian carcinoma, and blockade of this pathway can promote the apoptosis of the drug-resistant cells and reverse the drug-resistance. Moreover, p38MAPK-mediated apoptosis in paclitaxel-resistant ovarian carcinoma cells depends on the activation of p53. This project was supported by a grant from R&D program of Heilongjiang Province (No. GB05C402-11).     

The Relationship between p38MAPK and Apoptosis during Paclitaxel Resistance of Ovarian Cancer Cells

To investigate the relationship between p38 mitogen-activated protein kinase (p38MAPK) and cell apoptosis during the paclitaxel resistance of ovarian carcinoma cell lines, flow cytometry (FCM) and PI staining were employed to determine the effect of p38MAPK inhibitor SB203580 on the apoptosis of A2780/Taxol cells, a drug-resistant human ovarian carcinoma cell line. p38MAPK protein expression in SB203580-treated cells was immunochemically measured. The 50% inhibition concentration (IC50) of paclitaxel on A2780/Taxol cells was determined by MTT assay. MDR-1 mRNA, and expression of p38MAPK and phospho-p53 protein were detected by RT-PCR and West- ern blotting, respectively. The apoptosis rate of A2780/Taxol cells was (19.7±1.04)% 24 h after SB203580 treatment. A significant difference in apoptosis rate was found among experiment group, control group and untreated group (P<0.05). The relative reversal rate of A2780/Taxol cells to pacli- taxel was (57.18±2.01)%. As compared with the control group and the untreated group, p38MAPK protein and MDR-1 mRNA in SB203580-treated cells was substantially decreased. The expression of p53 protein was significantly increased. It is concluded that p38MAPK pathway is related to pacli- taxel resistance of ovarian carcinoma, and blockade of this pathway can promote the apoptosis of the drug-resistant cells and reverse the drug-resistance. Moreover, p38MAPK-mediated apoptosis in pa- clitaxel-resistant ovarian carcinoma cells depends on the activation of p53.     

Construction of Three-dimensional In Vitro Culture Model of Ovarian Carcinoma and the Study of Its Multicellular Drug Resistance

The resistance to chemotherapeutic drugs is one of the main cause of failure of the treatment of solid tumors. In ovarian carcinoma, both single cell and multicellular aggregates are found in patients’ ascitic fluid[1]. As our previous study showed that, in contrast to monolayer cell (MC) cultured in vitro, the solid tumors had similar bio-logical behaviors as compared with multicellular aggre-gates and displayed resistant to a wide variety of cyto-toxic agents[2, 3]. The examination of mult…     

紫杉醇纳米复合物体内体外抗宫颈癌活性评价

 目的 利用二硫键共价链接紫杉醇（paclitaxel，PTX）与荧光介孔二氧化硅纳米粒（fluorescent mesoporoussilica nanoparticles，FMSN），形成一种可控药物投递系统（controlled drug delivery system，CDDS），并用体内体外实验评价其抗宫颈癌活性。方法 HeLa细胞分别与PTX、PTX-FMSN和空白对照共培养。细胞IQ工作站和流式细胞仪检测细胞的生长和凋亡情况。血检和组织病理学研究评价药物抗肿瘤作用和毒性作用及不良反应。结果 体外研究表明，PTX-FMSN与PTX溶液相比，对HeLa细胞具有相似的抑制细胞增殖和促凋亡作用。经PTX和PTX-FMSN治疗的荷瘤裸鼠，HeLa细胞坏死率并无明显差异，但在相同剂量下，PTX-FMSN的毒性作用及不良反应明显小于PTX。结论 由于毒性作用及不良反应的降低，这种氧化还原性CDDS具有被应用于宫颈癌临床治疗的美好前景。     

沉默RRM1可逆转乳腺癌细胞MCF-7/R对紫杉醇的耐药性

目的阐明沉默核苷酸还原酶M1亚基（RRM1）对乳腺癌耐药细胞MCF-7/R逆转耐药的作用。方法通过高浓度紫杉醇诱 导耐药株MCF-7/R;运用Kaplan-Meier Plotter绘制RRM1基因的生存曲线;通过siRNA沉默MCF-7/R细胞中RRM1基因表达, 并用Western blot 和qRT-PCR方法检测蛋白和基因水平的表达,筛选出高效特异的si-RRM1 序列;将该si-RRM1 序列转染 MCF-7/R细胞,筛选得到能稳定抑制RRM1基因表达的细胞株MCF-7/R/siRNA;四甲基偶氮唑盐（MTT）法和5-乙炔基-2’脱氧 尿嘧啶核苷（EdU）染色法检测RRM1沉默后MCF-7/R细胞增殖能力的变化;流式细胞术检测细胞周期和凋亡,并观察周期、凋 亡相关蛋白的变化;构建裸鼠皮下移植瘤模型,观察沉默RRM1后给予紫杉醇治疗对裸鼠体内抑瘤效果的影响。结果生存曲 线分析显示RRM1基因表达与乳腺癌患者的生存率呈负相关（P=0.000）;MCF-7/R细胞中证实RRM1蛋白和mRNA表达水平 较MCF-7细胞均显著升高（P<0.01）;si-RRM1序列筛选中,转染si-RRM1-04组细胞的RRM1蛋白和mRNA表达量降低最为显 著（P<0.001）;沉默RRM1后,MCF-7/R细胞对紫杉醇的敏感性显著增加,细胞晚期凋亡比例明显升高（P<0.001）,同时降低Akt 蛋白的磷酸化并抑制凋亡蛋白Bcl-2 的表达,促进p53 蛋白表达水平的增加（P<0.001）;裸鼠实验显示,与si-NC组相比,沉默 RRM1后给予紫杉醇治疗可显著抑制裸鼠体内肿瘤的生长（P<0.001）。结论沉默RRM1可通过诱导细胞凋亡增加提高MCF- 7/R细胞化疗敏感性,逆转乳腺癌紫杉醇化疗耐药。     

德育哲学视野下实习医学生社会主义核心价值观教育探析

目的：探讨灵芝三萜组分（GLE）增强紫杉醇（PTX）诱导人表皮生长因子受体2阳性（HER2＋）乳腺癌细胞凋亡的作用和机制。方法磺酰罗丹明B（SRB）法和台盼蓝染色计数法检测细胞增殖活性。CompuSyn软件分析药物相互作用。免疫印迹法检测蛋白表达。采用人乳腺癌细胞裸鼠移植瘤模型研究体内抗肿瘤作用。结果体外实验表明,GLE与PTX协同抑制SKBR‐3细胞的增殖和诱导细胞凋亡,并协同诱导细胞凋亡相关蛋白的表达和阻断HER2信号通路的传导。体内动物实验表明,GLE增强 PTX抗 HER2＋乳腺癌的作用。结论GLE 与PTX 在体内外对HER2＋乳腺癌SKBR‐3细胞具有协同抑制作用。     

Effect of Mad2 on paclitaxel-induced cell death in ovarian cancer cells

In this article, the status of spindle assembly checkpoint and the alteration of its major component, Mad2 protein level were examined in A2780 and SKOV3 ovarian cancer cell lines.Recombinant eukaryotic expression plasmid pEGFP-Mad2 was transfected into paclitaxel-resistant SKOV3 cells and Mad2 protein was knocked down by Mad2-specific siRNA in paclitaxel-sensitive A2780 cells.Then the expression level of Mad2 gene was detected by Western blotting.Flow cytometry revealed that SKOV3 cells were not fully arrested in G2/M phase in contrast to A2780 cells in the presence of paclitaxel.However, paclitaxel sensitivity assay showed that sensitivity to paclitaxel was reversed after the transfection in both cell lines in terms of number of cells arrested at G2/M phase and the expression of Bcl-2 was significantly changed.These results suggest that weakened spindle checkpoint with reduced expression of Mad2 is associated with resistance to paclitaxel in ovarian cells and Bcl-2 may be involved in this process.     

RNAi抑制Aurora B激酶对卵巢癌A2780细胞增殖和周期的影响

目的研究RNAi抑制Aurora B激酶对卵巢癌A2780细胞增殖和周期的影响。方法采用RNAi方法,将AURKB RNAi转入A2780细胞,RT-PCR、Western blot检测Aurora B mRNA和蛋白的表达,MTT检测A2780细胞增殖情况,流式细胞术检测A2780细胞周期改变。结果①通过RT-PCR、Western blot检测到人类5种卵巢癌细胞株A2780、SKOV3、CAOV3、A2780/taxol及AD6中均明显表达Aurora B mRNA和蛋白;②A2780细胞转染AURKBRNAi后,Aurora B mRNA和蛋白的表达明显下降,转染浓度至200 pmol/L RNAi 48 h后,Aurora B mRNA和蛋白的表达被完全抑制;③MTT检测和锥虫蓝染色结果显示,于转染200 pmol/L AURKB RNAi第4天开始,A2780细胞增殖明显受到抑制,吸光度值与空白对照组和阴性对照组相比,差异有统计学意义(P<0.05);④Flow cytometry检测显示,转染200 pmol/L AURKB RNAi 24 h,大量A2780细胞进入有丝分裂期,并形成多倍体细胞,于72 h多倍体细胞比例达到峰值20.54%,转染后96 h转染组细胞凋亡率(11.67%)显著高于对照组(0.57%);⑤Hoechst 33258染色观察细胞凋亡结果显示,与A2780对照和阴性对照相比,转染200 pmol/L浓度AURKB RNAi 96 h后A2780细胞凋亡明显增多。结论 Aurora B的抑制使A2780细胞增殖受到明显抑制;导致多倍体形成,使细胞基因组严重不稳定,最终导致细胞凋亡,Aurora B可能是卵巢癌治疗的有效分子靶点。     

肿瘤错配修复基因PMS2及活化Akt1在不同卵巢癌细胞株中的表达及相关性

目的：检测Akt1、P-AktS473和PMS2蛋白在人类不同卵巢癌细胞株（A2780、Caov3、C13*和ES2）中的表达水平及相关性。方法应用Western blot检测Akt1、P-Akt S473和PMS2蛋白分别于A2780、Caov3、C13*和ES2细胞中表达水平;应用Akt1激动剂胰岛素样生长因子-1（IGF-1）及Akt1特异性抑制剂API-2调节Akt1活化水平,观察PMS2蛋白表达水平变化。结果 Akt1,P-Akt S473及PMS23种蛋白在A2780,Caov3,C13*和ES2卵巢癌细胞内均表达,但表达水平高低不一,即Akt1的活化形式P-Akt S473与PMS2蛋白表达呈负相关;应用IGF-1上调Akt1的活性后,ES2和Caov3中PMS2表达水平明显下降,且与IGF-1的作用存在时间依赖性;应用特异性抑制剂 API-2抑制Akt1的活性后,A2780中 PMS2表达水平明显升高,且与API-2的作用存在时间依赖性。结论人类卵巢癌细胞中PMS2蛋白的表达水平可能受活化Akt1的直接调控。     

IL-17A促进卵巢癌顺铂耐药的体外机制探讨

目的:探究IL-17A促进卵巢癌顺铂（DDP）耐药的体外机制。方法:应用流式细胞术分析外源性rhIL-17A对DDP诱导的A2780（顺铂敏感卵巢癌细胞株）和OVCAR3（顺铂耐药卵巢癌细胞株）细胞的凋亡和周期分布变化的影响,并以IL-17RAmAb进行相应的阻断实验。结果:rhIL-17A对A2780和OVCAR3细胞的凋亡无显著影响;但可显著降低DDP对A2780和OVCAR3细胞的毒性作用（P<0.05）,以IL-17RAmAb进行阻断实验可部分消除rhIL-17A对DDP诱导的A2780和OVCAR3细胞凋亡的阻滞作用（P<0.05）。rhIL-17A对A2780和OVCAR3细胞的周期分布无显著影响;但可显著抑制 DDP诱导的A2780和OVCAR3细胞周期阻滞（P <0.05）,使A2780和OVCAR3细胞的G0/G1期比例增加,G2+S期比例减少。结论: IL-17A可通过IL-17RA抑制DDP诱导的卵巢癌细胞凋亡,同时可抑制DDP诱导的卵巢癌细胞周期阻滞,从而加剧以DDP为基础的卵巢癌化疗耐药性。